Jane Hook
YOU?
Author Swipe
View article: Discriminative Accuracy of CHA2DS2-VASc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke Risk in Cardiac Amyloidosis and Atrial Fibrillation
Discriminative Accuracy of CHA2DS2-VASc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke Risk in Cardiac Amyloidosis and Atrial Fibrillation Open
CA with AF carries a high risk of ischemic stroke that is not accurately predicted by the CHA2DS2-VASc score. Our proposed model (E-CHADS) identifies three new variables (ESRD, dementia, and cancer) that have higher discriminative accuracy…
View article: The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma Open
Background Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other cancers. The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)), showed a s…
View article: MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe
MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe Open
Introduction Immune checkpoint inhibitors (ICIs) are immunomodulatory molecules that downregulate T-cell inhibiting-receptors or ligands to promote an enhanced anti-tumour response. Ipilimumab is a human monoclonal antibody directed agains…